HALO Modules

Maximizing use of HALO® and HALO AI for a comprehensive image analysis for HUMAN Brain FFPE Tissue samples in Alzheimer’s Disease

25 May 2022 | In this 60-min webinar, Learn how HALO and HALO AI are advancing neuropathology research at the UW Medicine Biorepository and Integrated Research (BRaIN) laboratory

Maximizing use of HALO® and HALO AI for a comprehensive image analysis for HUMAN Brain FFPE Tissue samples in Alzheimer’s Disease Read More »

Masterclass Webinar: Optimizing RNAscope Image Analysis

05 May 2022 | In this 60-min webinar, Dr. Ghislaine Lioux will present solutions to common RNAscope image analysis challenges including how to optimize color deconvolution, nuclear segmentation, and how to manage spot clusters

Masterclass Webinar: Optimizing RNAscope Image Analysis Read More »

Whole-slide Quantitative RNAscope Image Analysis: Applications and Methods

20 April 2022 | In this 2-hour event, learn from three experts in RNAscope image analysis with HALO® as they present their scientific research, share RNAscope tips and tricks, and participate in a panel discussion.

Whole-slide Quantitative RNAscope Image Analysis: Applications and Methods Read More »

Optimizing quantitative analysis of highly multiplexed CODEX images in HALO

31 March 2022 | In this webinar, Dr. Noemi Kedei, a staff scientist at the Collaborative Protein Technology Resource core of the Center for Cancer Research (CCR) at the National Cancer Institute, will present a comprehensive CODEX workflow, from image acquisition to image processing and HALO image analysis. Dr. Kedei leads the core facility that provides this technology as service to CCR investigators, including project consultation and design, antibody panel customization, tissue staining and imaging, image processing, and data management. Since Dr. Kedei and team were an early adopter of the CODEX platform, they have acquired deep expertise in CODEX, having imaged hundreds of mouse and human fresh frozen and FFPE tissues in support of multiple NCI/CCR projects.

Optimizing quantitative analysis of highly multiplexed CODEX images in HALO Read More »

Tumor-specific tumor-resident cytotoxic T cells predict recurrence in stage III melanoma patients treated with adjuvant immunotherapy

20 January 2022 | In this 60-minute webinar, learn how HALO and HALO AI collaborate to perform tissue and cell segmentation, quantification of T-cell subsets in tumor regions, and spatial analysis .

Tumor-specific tumor-resident cytotoxic T cells predict recurrence in stage III melanoma patients treated with adjuvant immunotherapy Read More »

Bench-to-Bedside Transition of Novel HALO® Assays into Clinical Trials with HALO AP®

10 December 2021 | In this 1-hour webinar, featured speakers will demonstrate end-to-end how to develop a quantitative assay in HALO and transition it into clinical trials using HALO AP.

Bench-to-Bedside Transition of Novel HALO® Assays into Clinical Trials with HALO AP® Read More »

2021 Masterclass: Deep Dive into AI-Based Nuclear Segmentation and Phenotyping Part II

04 November 2021 | Following up on our HALO 3.2 Masterclass: Deep Dive into AI-based Nuclear Segmentation and Phenotyping, in this Masterclass webinar with HALO 3.3, we will further delve into options for AI-based nuclear segmentation and phenotyping.

2021 Masterclass: Deep Dive into AI-Based Nuclear Segmentation and Phenotyping Part II Read More »

THYROID MALT LYMPHOMA:  SELF-HARM TO GAIN POTENTIAL T-CELL HELP

28 October 2021 | The development of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) is driven by chronic inflammatory responses and acquired genetic changes.  To investigate its genetic bases, we performed targeted sequencing of 93 genes in 131 MALT lymphomas including 76 from the thyroid. We found frequent deleterious mutations of TET2 (86%), CD274 (53%), TNFRSF14 (53%) and TNFAIP3 (30%) in thyroid MALT lymphoma.

THYROID MALT LYMPHOMA:  SELF-HARM TO GAIN POTENTIAL T-CELL HELP Read More »

Automated detection and quantitation of gastric immune cells in a mouse model of Helicobacter pylori­-driven preneoplastic progression

21 October 2021 | Gastric cancer is the fourth-leading cause of cancer death worldwide. About 80% of cases are attributable to infection with the bacterium Helicobacter pylori (Hp). Untreated Hp infection causes lifelong stomach inflammation that does not eradicate the bacterium. In some individuals, stomach inflammation leads to preneoplastic progression, a series of sequential tissue changes including loss of gastric acid-producing parietal cells, metaplasia, dysplasia, and finally cancer.

Automated detection and quantitation of gastric immune cells in a mouse model of Helicobacter pylori­-driven preneoplastic progression Read More »

Scroll to Top